“EFFECT OF ANTI-HYPERTENSIVE DRUGS FACTORS ON SYSTOLIC BLOOD PRESSURE (SBP) IN ELDERLY POPULATION: A STUDY FROM A TERTIARY CARE HOSPITAL IN DELHI”
Main Article Content
Keywords
Elderly population, Telmisartan, Systolic Hypertension, Combination Drug Therapy Introduction
Abstract
Background: Hypertension (HTN) is a major public health problem in all age group, but isolated systolic hypertension (ISH) is the commonest form of hypertension in elderly population, and it is a better predictor of cardiovascular morbidity and mortality compared to diastolic blood pressure.
AIM: Aim of the present study is to evaluate the effectiveness of various anti-hypertensive drugs and their combinations on systolic blood pressure in elderly patients.
Materials & Method: This prospective observational study was conducted on the patient attending OPD & IPD of HAHC Hospital, Jamia Hamdard, New Delhi. All the elderly hypertensive with elevated systolic BP were included in the study, after explaining the details about the study and taking written consent data were recorded on a proforma. The patients were followed every regularly and the effect of drugs on SBP were assessed and recoded at monthly interval. Data were analyzed by using IBM SPSSv20.
Results: This study documented that among the 220 hypertensive patients who completed the study 51% were female. The maximum numbers of patients were from of age group of 56 to 65 years (44.54%). This study also shows that 40.90% patients were tobacco user. In the single drug therapy telmisartan (40mg) shows best efficacy (21.61% reduction in SBP) followed by ramipril (19.3%) and amlodipine (17.15%). In two drug therapy Carvedilol + thiazide diuretic shows 27.21% reduction in systolic blood pressure followed by CCB+ diuretics 26.7% reduction, CCB+ β1 blocker ( 24.57%reduction), ARBS + CCB (19.03% reduction). In the triple drug therapy CCB+ β1 blocker + ARBs show 23.91% reduction in systolic blood pressure followed by CCB+ ACEI + diuretic shows 21.60%reduction.
Conclusion: Uncontrolled or poorly controlled systolic hypertension is a major risk factor for cardiovascular morbidity and mortality in the elderly population. Proper controlled of SBP by using appropriate medicine may improve the quality of life and productivity of the elderly population.
Our study shows that telmisartan as single drug therapy provides good control of SBP followed by ramipril and amlodipine but a combination of two drugs carvedilol with thiazide diuretic, a combination of CCB with beta blocker or ARBs with CCB provides over all better control of systolic hypertension in elderly population.
Elderly population, Telmisartan, Systolic Hypertension, Combination Drug Therapy Introduction
References
2. Thomas, S., The need for geriatric dental education in India: the geriatric health challenges of the millennium. International Dental Journal, 2013. 63(3): p. 130-136.
3. Van Crowder Jr, L., Agents, vendors, and farmers: An assessment of agricultural knowledge and technology generation, transfer and utilization in Imbabura Province, Ecuador. 1990: Cornell University.
4. Pal, A., et al., COPD disease knowledge, self-awareness and reasons for hospital presentations among a predominately Indigenous Australian cohort: a study to explore preventable hospitalisation. BMJ Open Respiratory Research, 2022. 9(1): p. e001295.
5. Stuckler, D. and S. Basu, Evaluating the health burden of chronic diseases. 2011: Oxford University Press Oxford.
6. Crooks, D.J., Development and testing of the Elderly Social Vulnerability Index (ESVI): A composite indicator to measure social vulnerability in the Jamaican elderly population. 2009, Florida International University.
7. Boutayeb, A. and S. Boutayeb, The burden of non communicable diseases in developing countries. International journal for equity in health, 2005. 4: p. 1-8.
8. Pimenta, E. and S. Oparil, Management of hypertension in the elderly. Nature Reviews Cardiology, 2012. 9(5): p. 286-296.
9. Becker, A., et al., Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease: 10-year followup of the Hoorn Study. European heart journal, 2003. 24(15): p. 1406-1413.
10. Rashid, A.M.U., et al., Prevalence of diabetes mellitus and hypertension among elderly population in Dhaka City. IJCS, 2017. 5(1): p. 175-180.
11. Boutayeb, A., The burden of communicable and non-communicable diseases in developing countries. Handbook of disease burdens and quality of life measures, 2010: p. 531.
12. Lewis, T.T., C.D. Cogburn, and D.R. Williams, Self-reported experiences of discrimination and health: scientific advances, ongoing controversies, and emerging issues. Annual review of clinical psychology, 2015. 11: p. 407-440.
13. Di Daniele, N., et al., Effects of caloric restriction diet on arterial hypertension and endothelial dysfunction. Nutrients, 2021. 13(1): p. 274.
14. Franklin, S.S., Hypertension in older people: part 1. The Journal of Clinical Hypertension, 2006. 8(6): p. 444-449.
15. Adler, A.J., et al., Reducing cardiovascular mortality through prevention and management of raised blood pressure. Glob Heart, 2015. 10(2): p. 111-22.
16. Yakoob, M.Y., et al., Impact of dietary and metabolic risk factors on cardiovascular and diabetes mortality in South Asia: analysis from the 2010 global burden of disease study. American journal of public health, 2016. 106(12): p. 2113-2125.
17. Gupta, R., Trends in hypertension epidemiology in India. Journal of human hypertension, 2004. 18(2): p. 73-78.
18. Kumar, J., Epidemiology of hypertension. Clinical Queries: Nephrology, 2013. 2(2): p. 56-61.
19. Dokunmu, T.M., et al., Cardiovascular risk factors in a suburban community in Nigeria. International Journal of Hypertension, 2018. 2018.
20. Sarki, A.M., et al., Prevalence of hypertension in low-and middle-income countries: a systematic review and meta-analysis. Medicine, 2015. 94(50).
21. Singh, R.B., et al., Prevalence and risk factors for prehypertension and hypertension in five Indian cities. Acta cardiologica, 2011. 66(1): p. 29-37.
22. Schensul, S.L., B.K. Nastasi, and R.K. Verma, Community-based research in India: a case example of international and transdisciplinary collaboration. American journal of community psychology, 2006. 38: p. 95-111.
23. Midha, T., et al., Isolated systolic hypertension and its determinants-A cross-sectional study in the adult population of Lucknow district in North India. Indian journal of community medicine: official publication of Indian Association of Preventive & Social Medicine, 2010. 35(1): p. 89.
24. Curb, J.D., et al., Long-term surveillance for adverse effects of antihypertensive drugs. Jama, 1985. 253(22): p. 3263-3268.
25. Prevention, J.N.C.o., T.o.H.B. Pressure, and N.H.B.P.E. Program, Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Vol. 6. 1997: Public Health Service, National Institutes of Health, National Heart, Lung ….
26. Sostres, C. and A. Lanas, Epidemiology of low dose aspirin damage in the lower gastrointestinal tract. Current pharmaceutical design, 2015. 21(35): p. 5094-5100.
27. Hardy, S., Blood Pressure-related Approaches to Reduce the Burden of Chronic Kidney Disease and Kidney Failure. The Atherosclerosis Risk in Communities (ARIC) study. 2017.
28. Rutan, G.H., et al., Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. Circulation, 1988. 77(3): p. 504-514.
29. Mandal, C., et al., Isolated systolic hypertension among the Bhotia of Uttaranchal. Hum Biol Rev, 2012. 1: p. 51-6.
30. Perry Jr, H.M., et al., Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). Jama, 2000. 284(4): p. 465-471.
31. GOTTLIEB, T.B., F.H. KATZ, and C.A. CHIDSEY III, Combined therapy with vasodilator drugs and beta-adrenergic blockade in hypertension: a comparative study of minoxidil and hydralazine. Circulation, 1972. 45(3): p. 571-582.
32. Eleftheriadou, I., et al., Choice of antihypertensive treatment in subjects with prediabetes. Is there a dream after the navigator. Current Vascular Pharmacology, 2011. 9(6): p. 715-722.
33. Basile, J., Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals. Integrated blood pressure control, 2010: p. 91-104.
34. Cutler, J.A. and B.R. Davis, Thiazide-type diuretics and β-adrenergic blockers as firstline drug treatments for hypertension. Circulation, 2008. 117(20): p. 2691-2705.
35. Martin, J., Hypertension guidelines: revisiting the JNC 7 recommendations. The Journal of Lancaster General Hospital, 2008. 3(3).
36. Sander, G.E., High blood pressure in the geriatric population: treatment considerations. The American Journal of Geriatric Cardiology, 2002. 11(4): p. 223232.
37. Staessen, J.A., et al., Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. Journal of hypertension, 2004. 22(4): p. 847-857.
38. Scott, L.J. and P.L. McCormack, Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs, 2008. 68: p. 1239-1272.
39. Kostis, J.B., et al., Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. The American journal of cardiology, 2005. 95(1): p. 29-35.
40. Bestic, M. and M.D. Reed, Pharmacology Review: Common Diuretics Used in the Preterm and Term Infant. NeoReviews, 2005. 6(8): p. e392-e398.
41. Manohar, P. and I.L. Piña. Therapeutic role of angiotensin II receptor blockers in the treatment of heart failure. in Mayo Clinic Proceedings. 2003. Elsevier.
42. Messerli, F.H., et al., Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use? Journal of the American College of Cardiology, 2018. 71(13): p. 14741482.
43. Wing, L.M., et al., A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. New England Journal of Medicine, 2003. 348(7): p. 583-592.
44. Franklin, S. and J. Neutel, Initial combination therapy for rapid and effective control of moderate and severe hypertension. Journal of Human Hypertension, 2009. 23(1): p. 4-11.
45. Fujita, M., et al., Treatment effects of renin-angiotensin system inhibitor and calcium channel blocker in patients with coronary artery narrowing (from the Japanese Coronary Artery Disease Study). Heart and vessels, 2010. 25: p. 453-459.
46. Jensen, C., P. Herold, and H.R. Brunner, Aliskiren: the first renin inhibitor for clinical treatment. Nature reviews Drug discovery, 2008. 7(5): p. 399-410.
47. Mason, R.P., Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis, 2002. 165(2): p. 191-199.
48. Opie, L., Pharmacological differences between calcium antagonists. European heart journal, 1997. 18(suppl_A): p. 71-79.
49. Na, J.O., et al., Results of a 14-week, multicenter, prospective, randomized, open-label, noninferiority clinical trial comparing the antihypertensive effect and edema incidence of lacidipine and amlodipine in older Korean patients with mild-to-moderate hypertension. Current Therapeutic Research, 2013. 74: p. 54-61.
50. Wang, J.-G., et al., Chinese trial on isolated systolic hypertension in the elderly. Archives of internal medicine, 2000. 160(2): p. 211-220.
51. Staessen, J.A., et al., Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet, 1997. 350(9080): p. 757-764.
52. Liu, L., et al., Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Journal of hypertension, 1998. 16(12): p. 18231829.
53. Britov, A. and M. Bystrova, New guidelines of the Joint National Committee (USA) on prevention, diagnosis and management of hypertension. From JNC VI to JNC VII. Kardiologiia, 2003. 43(11): p. 93-97.
54. Wong, T.Y. and R. McIntosh, Systemic associations of retinal microvascular signs: a review of recent population‐based studies. Ophthalmic and Physiological Optics, 2005. 25(3): p. 195-204.
55. Shrout, T., D.W. Rudy, and M.T. Piascik, Hypertension update, JNC8 and beyond. Current opinion in pharmacology, 2017. 33: p. 41-46.
56. Chadha, S., et al., Epidemiological study of coronary heart disease in urban population of Delhi. The Indian journal of medical research, 1990. 92: p. 424-430.
57. Pekka, J., T. Jaakko, and P. Pekka, Sex, Age. Cardiovascular Risk Factors, and Coronary Heart Disease. J Am Heart Assoc, 1999. 99: p. 165-72.
58. Chobanian, A.V., et al., Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. hypertension, 2003. 42(6): p. 1206-1252.
59. Ahluwalia, M. and S. Bangalore, Management of hypertension in 2017: targets and therapies. Current opinion in cardiology, 2017. 32(4): p. 413-421.
60. Kyvelou, S., et al., Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial. Hellenic J Cardiol, 2006. 47(1): p. 21-28.
61. Sydorchuk, L. and K. Amosova, Influence of pharmacogenetically determined treatment on parameters of peripheral hemodynamics in patients with arterial hypertension. 2011.
62. Xing, F., et al., Real role of β-blockers in regression of left ventricular mass in hypertension patients: Bayesian network meta-analysis. Medicine, 2017. 96(10).
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Nikhil Singh
Ph.D scholar, Department of Pharmacy, Sunrise University, Alwar, Rajasthan
Vivek Deniel
Research Supervisor, Department of Pharmacy, Sunrise University, Alwar, Rajasthan
Manmeet Singh
Research Supervisor, Department of Pharmacy, Sunrise University, Alwar, Rajasthan